Prof. Benoit Van den Eynde, co-founder of iTeos Therapeutics, is a distinguished figure in tumor immunology. He directs the Ludwig Cancer Research Brussels and holds positions at UCLouvain, the de Duve Institute in Brussels, and the University of Oxford. His groundbreaking work includes identifying early tumor antigens recognized by CD8+ T lymphocytes and revealing immunosuppressive mechanisms in the tumor microenvironment. With a medical degree and Ph.D. in immunology from UCLouvain, he has authored numerous publications and holds several patents, earning recognition such as the GlaxoSmithKline Prize and Joseph Maisin Prize in Biomedical Sciences.